ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Hodgkin Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma
Leukemia

Lymphoma trials near Paris, Île-de-France, FRA:

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (PlaTform)

This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas...

Enrolling
Peripheral T Cells Lymphoma (PTCL)
Drug: azacitidine
Drug: golcadomide

Phase 1, Phase 2

The Lymphoma Academic Research Organisation

Paris, France and 19 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Paris, France and 68 other locations

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Paris, France and 59 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Active, not recruiting
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

Paris, France and 104 other locations

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Drug: Lenalidomide
Drug: Odronextamab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Paris, France and 168 other locations

with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimm...

Enrolling
Peripheral T Cell Lymphoma
Relapse/Recurrence
Drug: Lacutamab
Drug: Gemcitabine

Phase 2

The Lymphoma Academic Research Organisation

Paris, France and 63 other locations

in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenal...

Enrolling
Primary CNS Lymphoma (PCNSL)
Drug: Epcoritamab

Phase 2

The Lymphoma Academic Research Organisation

Paris, France and 12 other locations

duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma...

Enrolling
Lymphoma
Drug: Duvelisib
Drug: Bendamustine

Phase 3

Secura Bio
Secura Bio

Paris, France and 42 other locations

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Active, not recruiting
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2

Celgene
Celgene

Paris, France and 56 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Paris, France and 48 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems